Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact
Entreprenorsstraket 10
GoCo House
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.70 | 46.30 | -0.52% |
| CAC 40 | 8,081.43 | 41.98 | -0.52% |
| DAX 40 | 25,266.53 | 144.10 | -0.57% |
| Dow JONES (US) | 51,349.98 | 161.61 | -0.31% |
| FTSE 100 | 10,679.99 | 25.27 | -0.24% |
| HKSE | 24,761.13 | 72.99 | -0.29% |
| NASDAQ | 26,939.37 | 3.34 | 0.01% |
| Nikkei 225 | 65,813.57 | 299.58 | 0.46% |
| NZX 50 Index | 13,819.53 | 5.30 | -0.04% |
| S&P 500 | 7,704.13 | 1.90 | -0.02% |
| S&P/ASX 200 | 8,661.20 | 40.80 | -0.47% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |